tacrolimus oral IBD
Selected indexed studies
- Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. (Gut, 2023) [PMID:35537812]
- Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. (Inflamm Bowel Dis, 2007) [PMID:17206694]
- Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. (Cochrane Database Syst Rev, 2022) [PMID:35388476]
_Worker-drafted node — pending editorial review._
Connections
tacrolimus oral IBD is a side effect of
Sources
- Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. (2023) pubmed
- Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. (2007) pubmed
- Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. (2022) pubmed
- Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres. (2013) pubmed
- Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse model. (2023) pubmed
- Optimizing conventional therapy for inflammatory bowel disease. (2008) pubmed
- Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. (2019) pubmed
- Medical therapy of inflammatory bowel disease for the 21st century. (1998) pubmed
- The mouth as a window: A multi-center retrospective study of oral extraintestinal manifestations of IBD and their management. (2026) pubmed
- Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review. (2021) pubmed